Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)
Deciphering the mechanisms of the pathogenesis of immune-mediated inflammatory rheumatic diseases (IIRDs) and designing a wide range of biological agents (BAs) are the major achievements of 21st century medicine. A new promising area of pharmacotherapy for IIRDs is associated with the design of so-c...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2020-02-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2845 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Deciphering the mechanisms of the pathogenesis of immune-mediated inflammatory rheumatic diseases (IIRDs) and designing a wide range of biological agents (BAs) are the major achievements of 21st century medicine. A new promising area of pharmacotherapy for IIRDs is associated with the design of so-called targeted oral medications that primarily include Janus kinase (JAK) inhibitors, called jakinibs. The first representative of the class of JAK inhibitors is tofacitinib (TOFA), which has been registered for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, and ulcerative colitis. The review (Part I) presents new data on the efficacy and safety of TOFA in RA and discusses the role of TOFA in the treatment of RA as part of the treat-to-target strategy and new EULAR recommendations. Part II of the review will provide data on the use of TOFA in other IIRDs. |
|---|---|
| ISSN: | 1995-4484 1995-4492 |